Nasdaq · CIK 0001433607
NSPR InspireMD, Inc.
Insider trading from SEC Form 4. Last filing 20 d ago. Close $0.52 on Oct 9, 2026, +8% from the 52-week low and -79% from the high.
In brief
InspireMD, Inc. (NSPR) has 51 SEC Form 4 filings on file from 7 insiders, the latest filed on Sep 23, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
20 open-market trades have been scored at NSPR. The newest: Paul Stuka (director) bought $18k of stock on May 27, 2026, filed May 29, 2026, scored 33 (weak). The largest of the 20 shown: Shane Thomas Gleason (Chief Commercial Officer) sold $190k on Jan 27, 2025, scored 27 (weak). 4 insiders bought within 14 days of each other around May 13, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at InspireMD, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | Paul Stuka director buy | $18k 20,000 shares | +3% | 0% from low-68% from high | |
| 27Weak | Shane Thomas Gleason Chief Commercial Officer sell | $190k 85,295 shares | -7% | +18% from low-15% from high | |
| 48Moderate | Paul Stuka director buy | $17k 15,000 shares | +2% | +6% from low-58% from high | |
| 58Moderate | Marvin Slosman CEO and President buy | $25k 21,000 shares | +1% | +9% from low-57% from high | |
| 45Moderate | Paul Stuka director buy | $88k 75,626 shares | +14% | +5% from low-59% from high | |
| 45Moderate | Paul Stuka director buy | $88k 75,626 shares | +14% | +5% from low-59% from high | |
| 61Notable | Gary S Roubin director buy | $106k 90,000 shares | +12% | +5% from low-58% from high | |
| 43Moderate | Paul Stuka director buy | $9,034 7,895 shares | +2% | +5% from low-58% from high | |
| 68Notable | Scott R. Ward director buy | $103k 89,250 shares | +60% | +5% from low-58% from high | |
| 23Weak | Paul Stuka director buy | $4,905 2,710 shares | +1% | +11% from low-51% from high | |
| 25Weak | Shane Thomas Gleason Chief Commercial Officer sell | $99k 61,194 shares | -5% | +1% from low-57% from high | |
| 28Weak | Paul Stuka director buy | $9,182 5,073 shares | +1% | +11% from low-51% from high | |
| 28Weak | Paul Stuka director buy | $9,436 5,073 shares | +1% | +15% from low-49% from high | |
| 28Weak | Paul Stuka director buy | $19k 10,130 shares | +3% | +18% from low-48% from high | |
| 15Weak | Paul Stuka director buy | $22k 13,431 shares | +4% | - | |
| 37Weak | Paul Stuka director buy | $50k 20,661 shares | +5% | - | |
| 35Weak | Marvin Slosman CEO and President buy | $25k 10,330 shares | +0% | - | |
| 41Moderate | Thomas J Kester director buy | $75k 30,991 shares | +8% | - | |
| 43Moderate | Gary S Roubin director buy | $100k 41,322 shares | +7% | - | |
| 37Weak | Gary S Roubin director buy | $127k 50,000 shares | +13% | +172% from low-39% from high |
Transactions
The newest 50 of 104 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | Michael Berman director | JOther Series J Warrant (right to buy)derivativeindirect: See Footnote | -30,625 | $0.00 | $0 | 30,624 | 20 d ago |
| Sep 18, 2026 | Gary S Roubin director | JOther Series J Warrant (right to buy)derivative | -15,313 | $0.00 | $0 | 15,312 | 20 d ago |
| Sep 18, 2026 | Paul Stuka director | JOther Series J Warrant (right to buy)derivativeindirect: See Footnote | -43,750 | $0.00 | $0 | 43,750 | 20 d ago |
| Sep 18, 2026 | Michael Berman director | JOther Series J Warrant (right to buy)derivativeindirect: See Footnote | +30,625 | $0.00 | $0 | 30,625 | 20 d ago |
| Sep 18, 2026 | Gary S Roubin director | JOther Series J Warrant (right to buy)derivative | +15,313 | $0.00 | $0 | 15,313 | 20 d ago |
| Sep 18, 2026 | Paul Stuka director | JOther Series J Warrant (right to buy)derivativeindirect: See Footnote | +43,750 | $0.00 | $0 | 43,750 | 20 d ago |
| Sep 18, 2026 | Gary S Roubin director | JOther Series K Warrant (right to buy)derivative | -30,624 | $0.00 | $0 | 0 | 20 d ago |
| Sep 18, 2026 | Paul Stuka director | JOther Series K Warrant (right to buy)derivativeindirect: See Footnote | -87,500 | $0.00 | $0 | 0 | 20 d ago |
| Sep 18, 2026 | Michael Berman director | JOther Series K Warrant (right to buy)derivativeindirect: See Footnote | -61,248 | $0.00 | $0 | 0 | 20 d ago |
| Sep 18, 2026 | Michael Berman director | JOther Series K Warrant (right to buy)derivativeindirect: See Footnote | +61,248 | $0.00 | $0 | 61,248 | 20 d ago |
| Sep 18, 2026 | Paul Stuka director | JOther Series K Warrant (right to buy)derivativeindirect: See Footnote | +87,500 | $0.00 | $0 | 43,750 | 20 d ago |
| Sep 18, 2026 | Gary S Roubin director | JOther Series K Warrant (right to buy)derivative | +30,624 | $0.00 | $0 | 30,624 | 20 d ago |
| May 27, 2026 | Paul Stuka director | POpen-market purchase Common Stock | +20,000 | $0.88 | $18k | 667,871 | May 29, 2026 |
| Jan 27, 2025 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -3,858 | $2.71 | $10k | 1,135,319 | May 21, 2026 |
| Jan 28, 2025 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -2,476 | $2.61 | $6,462 | 1,132,843 | May 21, 2026 |
| Jan 29, 2025 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -3,660 | $2.46 | $9,004 | 1,129,183 | May 21, 2026 |
| Jan 30, 2025 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -2,454 | $2.51 | $6,160 | 1,126,729 | May 21, 2026 |
| Jan 31, 2025 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -9,923 | $2.55 | $25k | 1,116,806 | May 21, 2026 |
| Feb 3, 2025 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -7,073 | $2.51 | $18k | 1,109,733 | May 21, 2026 |
| Feb 4, 2025 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -5,132 | $2.46 | $13k | 1,104,601 | May 21, 2026 |
| Feb 25, 2025 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -10,000 | $3.65 | $37k | 1,094,601 | May 21, 2026 |
| May 23, 2025 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -2,482 | $2.51 | $6,230 | 1,092,119 | May 21, 2026 |
| May 27, 2025 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -1,572 | $2.51 | $3,946 | 1,090,547 | May 21, 2026 |
| May 29, 2025 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -3,760 | $2.51 | $9,438 | 1,086,787 | May 21, 2026 |
| May 30, 2025 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -7,186 | $2.51 | $18k | 1,079,601 | May 21, 2026 |
| Feb 2, 2026 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -2,941 | $1.59 | $4,676 | 1,076,660 | May 21, 2026 |
| May 19, 2026 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -22,778 | $1.01 | $23k | 1,053,882 | May 21, 2026 |
| May 13, 2026 | Paul Stuka director | POpen-market purchase Common Stock | +10,000 | $1.16 | $12k | 642,871 | May 15, 2026 |
| May 14, 2026 | Paul Stuka director | POpen-market purchase Common Stock | +5,000 | $1.15 | $5,750 | 647,871 | May 15, 2026 |
| May 12, 2026 | Marvin Slosman CEO and President | POpen-market purchase Common Stock | +21,000 | $1.20 | $25k | 3,556,658 | May 13, 2026 |
| May 8, 2026 | Paul Stuka director | POpen-market purchase Common Stock10b5-1 | +65,626 | $1.16 | $76k | 622,871 | May 13, 2026 |
| May 11, 2026 | Paul Stuka director | POpen-market purchase Common Stock10b5-1 | +10,000 | $1.19 | $12k | 632,871 | May 13, 2026 |
| May 8, 2026 | Paul Stuka director | POpen-market purchase Common Stock10b5-1 | +65,626 | $1.16 | $76k | 622,871 | May 12, 2026 |
| May 11, 2026 | Paul Stuka director | POpen-market purchase Common Stock10b5-1 | +10,000 | $1.19 | $12k | 632,871 | May 12, 2026 |
| May 7, 2026 | Gary S Roubin director | POpen-market purchase Common Stock | +90,000 | $1.18 | $106k | 834,478 | May 8, 2026 |
| May 6, 2026 | Paul Stuka director | POpen-market purchase Common Stock | +1,517 | $1.12 | $1,699 | 525,221 | May 8, 2026 |
| May 6, 2026 | Scott R. Ward director | POpen-market purchase Common Stock | +15,995 | $1.15 | $18k | 163,841 | May 8, 2026 |
| May 7, 2026 | Paul Stuka director | POpen-market purchase Common Stock | +6,378 | $1.15 | $7,335 | 531,599 | May 8, 2026 |
| May 7, 2026 | Scott R. Ward director | POpen-market purchase Common Stock | +73,255 | $1.15 | $84k | 237,096 | May 8, 2026 |
| Dec 9, 2025 | Paul Stuka director | POpen-market purchase Common Stock | +2,710 | $1.81 | $4,905 | 391,628 | Feb 23, 2026 |
| Jan 15, 2026 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -2,909 | $1.58 | $4,593 | 1,197,462 | Feb 2, 2026 |
| Jan 16, 2026 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -2,250 | $1.61 | $3,627 | 1,195,212 | Feb 2, 2026 |
| Jan 20, 2026 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -2,955 | $1.59 | $4,710 | 1,192,257 | Feb 2, 2026 |
| Jan 21, 2026 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -17,593 | $1.62 | $29k | 1,174,664 | Feb 2, 2026 |
| Jan 22, 2026 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -8,411 | $1.57 | $13k | 1,166,253 | Feb 2, 2026 |
| Jan 27, 2026 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -4,781 | $1.66 | $7,956 | 1,161,472 | Feb 2, 2026 |
| Jan 28, 2026 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -12,395 | $1.65 | $20k | 1,149,077 | Feb 2, 2026 |
| Jan 29, 2026 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -5,000 | $1.65 | $8,250 | 1,144,077 | Feb 2, 2026 |
| Jan 30, 2026 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -2,900 | $1.63 | $4,730 | 1,141,177 | Feb 2, 2026 |
| Feb 2, 2026 | Shane Thomas Gleason Chief Commercial Officer | SOpen-market sale Common Stock | -2,000 | $1.60 | $3,208 | 1,139,177 | Feb 2, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Michael Bermandirector
- Shane Thomas GleasonChief Commercial Officer
- Thomas J Kesterdirector
- Gary S Roubindirector
- Marvin SlosmanCEO and President
- Paul Stukadirector
- Scott R. Warddirector
Questions about NSPR
Answered from the filings on this page, as of the latest one.
Are insiders buying NSPR?
No. In the last 90 days no insider at InspireMD, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade NSPR on the open market?
Paul Stuka (director) bought $18k of NSPR on May 27, 2026 and filed the Form 4 on May 29, 2026. InsiderTell scored 33 (weak).
How many insiders file Form 4 at InspireMD, Inc.?
7 people have filed a Form 4 at InspireMD, Inc., among them Michael Berman (director), Shane Thomas Gleason (Chief Commercial Officer), Thomas J Kester (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.